Targeted treatments with tyrosine kinase inhibitors (TKI) have become the first line therapy for patients with advanced lung adenocarcinoma bearing EGFR mutations or ALK rearrangement, thanks to the improved clinical response and tolerability profile of these drugs compared to standard chemotherapy [10, 11]. The gene discussed is ALK; the disease is lung adenocarcinoma.